for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

PetIQ Inc

PETQ.OQ

Latest Trade

27.33USD

Change

0.10(+0.37%)

Volume

16,684

Today's Range

27.13

 - 

27.71

52 Week Range

21.48

 - 

41.44

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
27.23
Open
27.26
Volume
16,684
3M AVG Volume
8.94
Today's High
27.71
Today's Low
27.13
52 Week High
41.44
52 Week Low
21.48
Shares Out (MIL)
28.22
Market Cap (MIL)
768.52
Forward P/E
21.78
Dividend (Yield %)
--

Latest Developments

More

Petiq Raises Full Year 2019 Outlook For Standalone PetIQ

PetIQ Says Unit Amends Credit Agreement To Raise Revolving Facility

Perrigo To Divest Animal Health Business For $185 Million In Cash

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About PetIQ Inc

PetIQ, Inc. is engaged in manufacturing and distributing pet medication and health and wellness products to the retail channel in the United States. The Company provides retail stores with third-party brands, including Frontline Plus, Heartgard Plus, PetAction Plus, Advecta II, Pet Lock Plus, Pet Lock Max, TruProfen and Heartshield. It distributes the products through veterinarian, retail and e-commerce channels. The Company offers its products in a range of categories, including Rx Medications, OTC Medications and Supplies, and Health and Wellness Products. Rx Medications offering includes heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics and other specialty medications. The Company manufactures Heart Shield Plus, version of Heartgard Plus, which prevents heartworm infection in dogs. The Company also manufactures TruProfen, the version of Rimadyl, which treats arthritis in dogs. OTC Medications and Supplies include flea and tick control products.

Industry

Food Processing

Contact Info

923 S Bridgeway Pl

+1.208.9398900

https://petiq.com/

Executive Leadership

McCord Christensen

Chairman of the Board, Chief Executive Officer

Susan Sholtis

President

John Newland

Chief Financial Officer

Michael A Smith

Executive Vice President, Products

Mark L. First

Lead Independent Director

Key Stats

1.33 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.3K

2018

0.5K

2019(E)

0.7K
EPS (USD)

2017

1.280

2018

0.770

2019(E)

1.263
Price To Earnings (TTM)
130.81
Price To Sales (TTM)
1.26
Price To Book (MRQ)
2.72
Price To Cash Flow (TTM)
39.01
Total Debt To Equity (MRQ)
36.82
LT Debt To Equity (MRQ)
35.99
Return on Investment (TTM)
2.11
Return on Equity (TTM)
1.49

Latest News

BRIEF-PetIQ, Inc. Enters Into Definitive Agreement To Acquire VIP Petcare

* PETIQ INC - ACQUISITION ANTICIPATED TO GENERATE APPROXIMATELY $450 MILLION TO $500 MILLION IN COMBINED COMPANY PRO FORMA 2018 NET SALES

BRIEF-Park West Asset Management LLC Reports 5.5 Percent Passive Stake In Petiq Inc

* PARK WEST ASSET MANAGEMENT LLC REPORTS 5.5 PERCENT PASSIVE STAKE IN PETIQ INC AS OF NOVEMBER 28 - SEC FILING Source text: (http://bit.ly/2nHqoDX) Further company coverage:

BRIEF-Petiq Q2 sales up 42.3 pct to $87.2 mln

* Petiq Inc reports second quarter fiscal 2017 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up